BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19449284)

  • 1. Stathmin as a marker for malignancy in pheochromocytomas.
    Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
    Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
    Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
    Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
    Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
    Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors.
    Komminoth P; Roth J; Schröder S; Saremaslani P; Heitz PU
    Lab Invest; 1995 Apr; 72(4):424-31. PubMed ID: 7723281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
    Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
    J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
    Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
    Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
    Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas.
    Guillemot J; Barbier L; Thouennon E; Vallet-Erdtmann V; Montero-Hadjadje M; Lefebvre H; Klein M; Muresan M; Plouin PF; Seidah N; Vaudry H; Anouar Y; Yon L
    Ann N Y Acad Sci; 2006 Aug; 1073():527-32. PubMed ID: 17102121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.
    Thouënnon E; Pierre A; Tanguy Y; Guillemot J; Manecka DL; Guérin M; Ouafik L; Muresan M; Klein M; Bertherat J; Lefebvre H; Plouin PF; Yon L; Anouar Y
    Endocr Relat Cancer; 2010 Sep; 17(3):637-51. PubMed ID: 20483910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
    Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
    Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.
    Saffar H; Sanii S; Heshmat R; Haghpanah V; Larijani B; Rajabiani A; Azimi S; Tavangar SM
    Am J Clin Pathol; 2011 Mar; 135(3):454-60. PubMed ID: 21350102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of telomerase activity in malignant pheochromocytoma.
    Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
    Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
    Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of urotensin II mRNA in normal adrenal medulla and pheochromocytoma tissues].
    Liu GQ; Zeng ZP; Li HZ; Fan XR; Liu DM; Tong AL; Zheng X
    Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1225-8. PubMed ID: 12930635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma.
    Sangoi AR; McKenney JK
    Am J Surg Pathol; 2010 Mar; 34(3):423-32. PubMed ID: 20154585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
    Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
    Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malignant pheochromocytoma. A case report and comments on a rare pathology].
    Boneschi M; Erba M; Rinaldi P; Cusmai F; Miani S
    Minerva Chir; 1999; 54(1-2):73-8. PubMed ID: 10230231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stathmin immunoreactivity in phaeochromocytomas and paragangliomas: differential expression between benign and malignant neoplasms.
    Lin WC; Chen SC; Chuang YT; Kuo KL; Huang KH
    Asian J Surg; 2011 Jan; 34(1):15-22. PubMed ID: 21515208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
    Salmenkivi K; Haglund C; Ristimäki A; Arola J; Heikkilä P
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5615-9. PubMed ID: 11701743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.